Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
0.3140
-0.0050 (-1.57%)
At close: Sep 11, 2026, 4:00 PM EDT
0.3150
+0.0010 (0.32%)
After-hours: Sep 11, 2026, 7:52 PM EDT
Jaguar Health Revenue
Jaguar Health had revenue of $1.23M in the quarter ending June 30, 2026, a decrease of -58.88%. This brings the company's revenue in the last twelve months to $27.82M, up 135.52% year-over-year. In the year 2025, Jaguar Health had annual revenue of $11.51M, down -1.52%.
Revenue (ttm)
$27.82M
Revenue Growth
+135.52%
P/S Ratio
0.06
Revenue / Employee
$591,809
Employees
47
Market Cap
1.62M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.51M | -178.00K | -1.52% |
| Dec 31, 2024 | 11.69M | 1.93M | 19.75% |
| Dec 31, 2023 | 9.76M | -2.20M | -18.36% |
| Dec 31, 2022 | 11.96M | 7.62M | 175.80% |
| Dec 31, 2021 | 4.34M | -5.05M | -53.81% |
| Dec 31, 2020 | 9.39M | 3.61M | 62.51% |
| Dec 31, 2019 | 5.78M | 1.36M | 30.77% |
| Dec 31, 2018 | 4.42M | 54.96K | 1.26% |
| Dec 31, 2017 | 4.36M | 4.22M | 2,981.61% |
| Dec 31, 2016 | 141.52K | -116.86K | -45.23% |
| Dec 31, 2015 | 258.38K | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Curis | 4.31M |
| Decoy Therapeutics | 227.63K |
| Biodexa Pharmaceuticals | 104.90K |
| Endovia Health Sciences | 32.09K |
| Virax Biolabs Group | 12.42K |
| Valion Bio | -86.00K |
JAGX News
- 3 days ago - Jaguar Health announces all pediatric MVID patients entered extension phase - TheFly
- 3 days ago - All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF) - Accesswire
- 5 days ago - Jaguar Health announces Neonorm Dog availability on Amazon - TheFly
- 9 days ago - Jaguar Health reports additional infant patient to receive crofelemer for IF - TheFly
- 9 days ago - Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) - Accesswire
- 18 days ago - Jaguar Health initiated commercial launch of Neonorm Dog - TheFly
- 18 days ago - Commercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs - Accesswire
- 24 days ago - Jaguar Health Transcript: Investor update - Transcripts